Market Overview

Goldman Sachs Reiterates Neutral Rating, $29 PT for Centene

Related CNC
UPDATE: Bank Of America Reiterates On Centene On Raised Estimates
Earnings Season Boosts Confidence; S&P Trades At Record Highs

In a company update published earlier today, the Goldman Sachs Group, Inc. reiterated its Neutral rating and $29.00 price target for Centene Corp. (NYSE: CNC).

Goldman Sachs went on to say “While the near-term downside risk looks higher, we believe margin pressure is likely to be episodic and that the long-term growth outlook remains robust as more states move their Medicaid spending into managed care (while health reform expands Medicaid coverage, starting in 2014, assuming the law stands). In addition, the conversion of Medicare-Medicaid dual eligibles could add $300 bn to the managed care industry top-line (we have identified $85 bn in annualized revenue from proposed dual eligible demonstrations so far).”

Centene Corp. closed yesterday at $28.20.

Latest Ratings for CNC

DateFirmActionFromTo
Jul 2014JP MorganMaintainsNeutral
Jul 2014Wells FargoDowngradesMarket Perform
Jul 2014CitigroupMaintainsSell

View More Analyst Ratings for CNC
View the Latest Analyst Ratings

Posted-In: Goldman Sachs Group Inc.Analyst Color Reiteration Analyst Ratings

 

Related Articles (CNC)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters